

Ms. Cathy Groupe
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Thursday, June 2, 2005

Dear Ms. Groupe:

I'm Charles Curry, President of the International Society on Hypertension in Blacks (ISHIB). I am writing to request five minutes during the public session of the Cardiovascular and Renal Drugs Advisory Committee meeting to review the BiDil NDA on Thursday, June 16, 2005.

The mission of ISHIB is to improve the health and life expectancy of ethnic minorities and eliminate racial and ethnic health disparities in cardiovascular disease through: professional and public education; targeted clinical research; and facilitation of the delivery of higher quality cardiovascular health care. Through the African American Heart Failure Trial, we have seen the black patient population, traditionally burdened at a disproportionately high rate

of heart failure, benefit from treatment as a result of research conducted in a targeted patient population. The A-HeFT results are very promising in bringing new, effective treatment options to those patients who need it most – African American heart failure patients – and ISHIB would like to show its support for A-HeFT and BiDil during the upcoming Advisory Committee meeting.

Thank you for all of your help.

Best Wishes,



Charles L. Curry, MD, FACC, FACP
President
International Society on Hypertension in Blacks
Professor of Medicine Emeritus
Howard University

9106 Fernwood Road
Bethesda, MD 20817
Home phone: (301) 469-7456
Email: kcandlc@aol.com

ISHIB